Payment overview · 2025
General Payments
$604.03
28 reported records · 12 companies
Healthcare provider profile · identity verified
Wonsock Shin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VIENNA, VA · NPI 1821098203
Verified facts
What the public records show
CMS Open Payments records show Wonsock Shin, M.D. received $604.03 in general payments during 2025 across 28 reported records.
PFIZER INC. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.35 | 24.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.01 | 13.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.08 | 11.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.33 | 11.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.32 | 8.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.91 | 7.3% | 2 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.39 | 6.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.33 | 4.0% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.17 | 4.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.66 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.34 | 3.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.14 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $604.03 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.10 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.08 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.33 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $64.97 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.77 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.77 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.44 | 2 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $36.39 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 64 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
75 | 48 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
51 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1917 | 610 |
| Losartan Potassium | Losartan Potassium | 780 | 235 |
| Metformin Hcl | Metformin Hcl | 643 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 624 | 190 |
| Omeprazole | Omeprazole | 565 | 252 |
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 133 |
| Tamsulosin Hcl | Tamsulosin Hcl | 417 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 410 | 128 |
| Celecoxib | Celecoxib | 338 | 161 |
| Lisinopril | Lisinopril | 282 | 82 |
| Alendronate Sodium | Alendronate Sodium | 273 | 91 |
| Pravastatin Sodium | Pravastatin Sodium | 267 | 76 |
| Finasteride | Finasteride | 258 | 88 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 248 | 71 |
| Azithromycin | Azithromycin | 243 | 184 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 88 |
| Simvastatin | Simvastatin | 235 | 69 |
| Donepezil Hcl | Donepezil Hcl | 191 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 52 |
| Januvia | Sitagliptin Phosphate | 163 | 43 |
| Montelukast Sodium | Montelukast Sodium | 163 | 70 |
| Metformin Hcl Er | Metformin Hcl | 162 | 43 |
| Mirtazapine | Mirtazapine | 138 | 63 |
| Pioglitazone Hcl | Pioglitazone Hcl | 131 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 122 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 36 |
| Prednisone | Prednisone | 118 | 69 |
| Lovastatin | Lovastatin | 113 | 31 |
| Carvedilol | Carvedilol | 111 | 36 |
| Cephalexin | Cephalexin | 111 | 84 |
| Farxiga | Dapagliflozin Propanediol | 100 | 29 |
| Furosemide | Furosemide | 100 | 34 |
| Glimepiride | Glimepiride | 99 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 98 | 72 |
| Glipizide Er | Glipizide | 95 | 34 |
| Valsartan | Valsartan | 94 | 28 |
| Ezetimibe | Ezetimibe | 93 | 38 |
| Meclizine Hcl | Meclizine Hcl | 92 | 52 |
| Sertraline Hcl | Sertraline Hcl | 91 | 34 |
| Fenofibrate | Fenofibrate | 86 | 26 |
| Ozempic | Semaglutide | 86 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 42 |
| Jardiance | Empagliflozin | 84 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 32 |
| Lidocaine | Lidocaine | 80 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 25 |
| Naproxen | Naproxen | 77 | 42 |
| Prolia | Denosumab | 75 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 67 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 20 |
| Eliquis | Apixaban | 64 | 20 |
| Famotidine | Famotidine | 64 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 64 | 18 |
| Trazodone Hcl | Trazodone Hcl | 64 | 27 |
| Allopurinol | Allopurinol | 62 | 18 |
| Gabapentin | Gabapentin | 61 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 15 |
| Linzess | Linaclotide | 57 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 51 |
| Atenolol | Atenolol | 54 | 18 |
| Vascepa | Icosapent Ethyl | 54 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 26 |
| Tradjenta | Linagliptin | 52 | 16 |
| Glipizide | Glipizide | 51 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 51 | 51 |
| Licart | Diclofenac Epolamine | 50 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 18 |
| Valacyclovir | Valacyclovir Hcl | 40 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Alprazolam | Alprazolam | 38 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Lorazepam | Lorazepam | 38 | 11 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Metronidazole | Metronidazole | 36 | 24 |
| Sucralfate | Sucralfate | 34 | 22 |
| Cefuroxime | Cefuroxime Axetil | 33 | 25 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 31 | 17 |
| Levemir Flexpen | Insulin Detemir | 30 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | 18 |
| Colchicine | Colchicine | 26 | 12 |
| Lactulose | Lactulose | 26 | 15 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 18 |
| Minoxidil | Minoxidil | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Exelon | Rivastigmine | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $604.03 · 28 records | PFIZER INC. | AIRSUPRA, ELIQUIS, EVENITY, FARXIGA, GEMTESA, JARDIANCE, KISUNLA, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TEPEZZA, UBRELVY, Veozah, WELLBUTRIN, ZAVZPRET, ZEPBOUND, ZTLido | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error